Parathyroid Disorders. Группа авторов

[4].

      Cinacalcet, a calcimimetic, is approved for specific indications in PHPT by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The EMA approved the use of cinacalcet for patients with hypercalcemia who meet surgical criteria but in whom parathyroidectomy is not possible or not clinically “appropriate.” The FDA approval is for severe hypercalcemia in patients with PHPT who are unable to undergo parathyroidectomy. Adverse effects of cinacalcet include nausea, vomiting, diarrhea, and headache, but are uncommon when the single 30-mg daily dose is used [4].

      Alendronate, a bisphosphonate, improved BMD in patients with PHP. In patients who require both a reduction in serum calcium levels and an improvement in BMD, combination therapy with cinacalcet and alendronate is reasonable, but has only been studied in a retrospective manner [4].

      References

1Silva BC, Bilezikian JP: Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol 2015;22:41–50.

2Bandeira F, Griz L, Chaves N, Carvalho NC, Borges LM, Lazaretti-Castro M, Borba V, Castro LC, Borges JL, Bilezikian J: Diagnosis and management of primary hyperparathyroidism – a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metabol 2013;57:406–424.

3Yu N, Donnan PT, Murphy MJ, Leese GP: Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol 2009;71:48.

4Bilezikian JP, Cusano NE, Khan AA, Liu J-M, Marcocci C, Bandeira F: Primary hyperparathyroidism. Nat Rev Dis Primers 2016;19:16033.

5Bandeira F, Correia A: Clinical presentation of primary hyperparathyroidism: a global perspective; in Bilezikian J, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT Jr (eds): The Parathyroids, ed 3. Cambridge, Academic Press, 2015, pp 309–314.

6Bilezikian JP, Bandeira L, Khan A, Cusano NE: Hyperparathyroidism. Lancet 2018;391:168–178.

7Horwitz MJ, Hodak SP, Stewart AF: Non-parathyroid hypercalcemia; in CJ Rosen (ed): Primer on the metabolic bone diseases and disorders of mineral metabolism, ed 8. Hoboken, Wiley-Blackwell, 2013, pp 562–571.

8Ziegler R: Clinical picture of humoral hypercalcemia of malignancy. Recent Results Cancer Res 1994;137:107–113.

9Stewart AF: Hypercalcemia associated with cancer. N Engl J Med 2005;352:373–379.

10Evans KN, Taylor H, Zehnder D, Kilby MD, Bulmer JN, Shah F, Adams JS, Hewison M: Increased expression of 25-hydroxyvitamin D-1α-hydroxylase in dysgerminomas: a novel form of humoral hypercalcemia of malignancy. Am J Pathol 2004;165:807–813.

11Brickman AS: Disorders of calciotropic hormones in adults; in Lavin N (ed): Manual Endocrinology and Metabolism. Philadelphia, Lippincott Eilliams & Wilkins, 2014, pp 293–323.

12Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiafico RA, Pulvirenti I, Hawa G, Tringali G, Fiore CE: Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J Clin Endocrinol Metab 2010;95:2248–2253.

13Herfarth K, Schmidt-Gayk H, Graf S, Maier A: Circadian rhythm and pulsatility of parathyroid hormone secretion in man. Clin Endocrinol 1992;37:511–519.

14Schmitt CP, Schaefer F, Bruch A, Veldhuis JD, Schmidt-Gayk H, Stein G, Ritz E, Mehls O: Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. J Clin Endocrinol Metab 1996;81:4236–4243.

15Abood A, Vestergaard P: Increasing incidence of primary hyperparathyroidism in Denmark. Dan Med J 2013;60:A4567.

16Dalemo S, Hjerpe P, Bostrom Bengtsson K: Diagnosis of patients with raised serum calcium level in primary care, Sweden. Scand J Prim Health Care 2006;24:160–165.

17Griebeler ML, Kearns AE, Ryu E, Thapa P, Hathcock MA, Melton LJ 3rd, Wermers RA: Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J Clin Endocrinol Metab 2016;101:1166–1173.

18Khan AA, Hanley DA Rizzoli R, Bollerslev J, Young JEM, Rejnmark L, et al: Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 2017;28:1–19.

19Pallan S, Rahman MO, Khan AA: Diagnosis and management of primary hyperparathyroidism. BMJ 2012;344:e1013.

20El-Hajj Fuleihan G, Brown EM: Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism; in Bilezikian JP, Marcus R, Levine MA, Marcocci C, Silverberg SJ, Potts JT (eds): The Parathyroids: Basic and Clinical Concepts, ed 3. London, Academic Press, 2014.

21Nesbit MA, Hannan FM, Howles SA, Reed AA, Cranston T, Thakker CE, Gregory L, Rimmer AJ, Rust N, Graham U, Morrison PJ, Hunter SJ, Whyte MP, McVean G, Buck D, Thakker RV: Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet 2013;45:93–97.

22Shane E: Clinical review: parathyroid carcinoma. J Clin Endocrinol Metab 2001;86:485–493.

23Bilezikian JP, Khan AA, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J Clin Endocrinol Metab 2009;94:335–339.

24Khosla S, Melton LJ III, Wermers RA, Crowson CS, O’Fallon W, Riggs B: Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 1999;14:1700–1707.

25Silva BC, Boutroy S, Zhang C, McMahon DJ, Zhou B, Wang J, Udesky J, Cremers S, Sarquis M, Guo XD, Hans D, Bilezikian JP: Trabecular bone score (TBS) – a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2013;98:1963–1970.